A group of leading doctors have launched Sapphire Medical Clinic in London and want to enter the cannabis industry. The clinic will focus on cannabis treatments and  conventional pharmaceutical drugs and treatments. World High Life Plc. (NEX: LIFE) has a great interest in CBD investment & Medical Marijuana in the EU.

Dr. Mikael Sodergren, Managing Director, and Academic Lead at Sapphire Medical Clinics said: “Medicinal cannabis is a new and exciting field. But it is important that access to it is in a way that fits in with other treatment options. Our clinics based on the premise that doctors treat patients in the relevant condition. We have the expertise to prescribe medicinal cannabis in a way that fits in with other more conventional treatments.”

He continued “Also when we judge that to be in the best interest of the patients. Our service to patients will work on the basis of ‘we are specialists in your condition. Our aim is to help you get better which may involve medical cannabis and hemp production. We have the expertise to prescribe it’, rather than ‘come to us to try medical cannabis’. Operating in this way means that doctors can have the confidence to refer their patients to us. Patients can have the confidence that we will prescribe medicinal cannabis in a way that fits in with other treatments.”

Founding doctors control Sapphire. Therefore the clinicians have complete freedom to prescribe any range of medicinal cannabis products from any available supplier. The Sapphire team also announced that they will build the first UK wide national database recording how patients react to medicinal cannabis and the European cannabis market.

Dr. Sodergren added: “The medical world needs more evidence about the efficacy of medicinal cannabis and hemp sector. Our national database will be a major contribution to meet that need.  It will be the first to have meaningful and consistent data on how medicinal cannabis helped when properly prescribed as part of a full treatment pathway.”

The Sapphire doctors have high qualifications in their respective fields. They include world-leading experts such as pain specialist Dr. Michael Platt, who frequently treats complex patients referred from the UK and abroad and has great experience in medical cannabis. In addition, the Sapphire team includes specialists in pediatric & adult neurology, palliative care, psychiatry, gastroenterology. Acute general medicine and neuropathic pain, and can replicate the multidisciplinary approach championed by the MHRA and NHS England as the safe and proper way to consider medicinal cannabis prescriptions.

It has been widely reported in the media that parents with children suffering from intractable epilepsy continue to experience difficulties in securing prescriptions for medical cannabis products containing THC.

Dr. Michael Platt, Medical Director of Sapphire Medical Clinics said: “As part of our portfolio of services we prepare to offer evaluative consultations to families with children who have epilepsy. This is for consideration of Cannabis-based products for medicinal use. There are concerns about the evidence base for the prescription of medicinal cannabis products containing THC to children.

Investment is necessary to boost the UK cannabis sector

The investment company World High Life (NEX: LIFE) speak about their attention to buying the British producer of cannabis oil. It is a great part of entering the European market. Several companies such as WHL have been listed to be in London.. The company has recently made moves to acquire Britain’s top hemp producer, Love Hemp, WHL plans to help Love Hemp expand into other European markets, starting with Germany in 2020. Companies like World High Life provide much needed capital for the nascent European Cannabis market, which is predicted to be the most valuable in the world within a decade.

Despite companies like WHL, investors are generally concerned about the lack of actionable research surrounding medical cannabis. These concerns reflect in the guidance from various medical bodies and in the understandable high degree of caution currently being shown by clinicians. But we are also aware of some anecdotal cases in which parents have been able to show that medicinal cannabis containing THC. They had a strong positive impact on the children concerned. Our pediatric neurology service will offer consultations to the families of the children concerned with an open mind but would reserve the right not to prescribe medicinal cannabis containing THC.”

The Harley Street based clinic is the first of what will grow into a national network. It will primarily work on a second opinion basis accepting referrals from GPs and other specialists.The Sapphire team have expressed their willingness to work with the NHS. This is to bring their unique approach of offering access to medicinal cannabis in a way that integrates with other treatment options to clinicians that currently lack the training and knowledge to prescribe medicinal cannabis. Efforts like this will provide much needed data that could help kickstart the British, and European, cannabis sector.